Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMP0YNU)

• Drug Name: RO7040547 Drug Info
• Synonyms: BITS7201A; RG7990

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Discontinued in Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMP0YNU

Molecule-Related Drug Atlas

Drug(s) Targeting Interleukin-17 (IL17)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Brodalumab	DMASDQ6	Plaque psoriasis	EA90.0	Approved	[3]
Bimekizumab	DMR9TF1	Plaque psoriasis	EA90.0	Approved	[4]
Ixekizumab	DMXW92T	Plaque psoriasis	EA90.0	Approved	[5]
CNTO-6785	DM6RQXB	Rheumatoid arthritis	FA20	Phase 2	[6]
ABT-122	DM23UQ9	Psoriatic arthritis	FA21	Phase 2	[7]
CJM112	DMTSVJM	Acne vulgaris	ED80	Phase 2	[8]
COVA322	DM824EG	Psoriasis vulgaris	EA90	Phase 1/2a	[9]
SHR-1314	DMADNY3	Plaque psoriasis	EA90.0	Phase 1/2	[4]
ABBV-257	DMCZI8L	Rheumatoid arthritis	FA20	Phase 1	[10]
ALX-0761	DMJ8ACF	Psoriasis vulgaris	EA90	Phase 1	[9]

Drug(s) Targeting Interleukin-13 (IL13)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tralokinumab	DM6ENSJ	Atopic dermatitis	EA80	Approved	[4]
Lebrikizumab	DMQP0X5	Severe asthma	CA23	Phase 3	[11]
Dexpramipexole	DM6KXAU	Eosinophilic asthma	CB02.0	Phase 3	[12]
Cendakimab	DM9LSBJ	Eosinophilic esophagitis	DA24.1	Phase 3	[13]
SAR-156597	DMUICJD	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[9]
PEGylated pitrakinra	DMBPJ9U	Asthma	CA23	Phase 2	[11]
Romilkimab	DMYEZ5J	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[14]
QAX-576	DMUWFI7	Allergic rhinitis	CA08.0	Phase 2	[15]
Anrukinzumab	DMTG2O0	Asthma	CA23	Phase 2	[16]
Dectrekumab	DM1H7UK	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[15]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-13 (IL13)	TT0GVCH	IL13_HUMAN	Inhibitor	[2]
Interleukin-17 (IL17)	TTG0MT6	IL17_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT02748642) A Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of BITS7201A in Healthy Volunteers and Participants With Mild Atopic Asthma. U.S. National Institutes of Health.
• [2] Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5.
• [6] Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov. 2015 Jan;14(1):11-2.
• [7] DOI: 10.1136/annrheumdis-2015-eular.4042
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [12] Therapeutic strategies for eosinophilic dermatoses. Curr Opin Pharmacol. 2019 Jun;46:29-33.
• [13] Biologics in eosinophilic gastrointestinal diseases. Ann Allergy Asthma Immunol. 2023 Jan;130(1):21-27.
• [14] A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607.
• [15] Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7.
• [16] Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.Gut.2015 Jun;64(6):894-900.